LivaNova PLC (NASDAQ:LIVN) Given Average Rating of “Buy” by Analysts

Shares of LivaNova PLC (NASDAQ:LIVN) have received a consensus rating of “Buy” from the seven analysts that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $69.17.

A number of research firms have recently issued reports on LIVN. Baird R W raised LivaNova from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, September 17th. Robert W. Baird raised their price target on LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a report on Thursday, October 31st. Needham & Company LLC reaffirmed a “buy” rating and set a $75.00 price objective on shares of LivaNova in a research report on Monday, November 25th. The Goldman Sachs Group assumed coverage on shares of LivaNova in a research report on Friday, October 4th. They issued a “buy” rating and a $65.00 price objective on the stock. Finally, StockNews.com downgraded shares of LivaNova from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 25th.

LivaNova Trading Up 1.3 %

Shares of NASDAQ:LIVN opened at $46.31 on Friday. LivaNova has a 52-week low of $43.15 and a 52-week high of $64.47. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37. The company has a market capitalization of $2.51 billion, a P/E ratio of 110.26 and a beta of 0.98. The company has a 50-day simple moving average of $50.52 and a 200 day simple moving average of $50.67.

Insider Activity

In other news, Director Francesco Bianchi sold 1,250 shares of the firm’s stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $50.99, for a total transaction of $63,737.50. Following the transaction, the director now directly owns 7,522 shares of the company’s stock, valued at approximately $383,546.78. This trade represents a 14.25 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.27% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On LivaNova

Several institutional investors and hedge funds have recently bought and sold shares of the company. Bank of New York Mellon Corp increased its stake in LivaNova by 4.2% in the second quarter. Bank of New York Mellon Corp now owns 506,105 shares of the company’s stock valued at $27,745,000 after acquiring an additional 20,275 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of LivaNova by 18.5% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 12,929 shares of the company’s stock valued at $709,000 after purchasing an additional 2,014 shares during the last quarter. Rhumbline Advisers increased its stake in shares of LivaNova by 0.4% in the 2nd quarter. Rhumbline Advisers now owns 183,132 shares of the company’s stock valued at $10,039,000 after purchasing an additional 659 shares during the last quarter. Wolverine Asset Management LLC acquired a new position in shares of LivaNova during the 2nd quarter worth $398,000. Finally, Mesirow Institutional Investment Management Inc. lifted its position in shares of LivaNova by 16.3% during the 2nd quarter. Mesirow Institutional Investment Management Inc. now owns 287,256 shares of the company’s stock worth $15,747,000 after buying an additional 40,281 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.